Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine
about
New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNALamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acidsCross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virusAnti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents.Preclinical aspects of lamivudine and famciclovir against hepatitis B virus.Development of resistance and perspectives for future therapies against hepatitis B infections: lessons to be learned from HIV.The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: a new strategy?Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.Treatment of chronic hepatitis B: new antiviral therapies.Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Hepatitis B virus genotyping among chronic hepatitis B individuals with resistance to Lamivudine in shahrekord, iran.Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.Quantitative detection of single base mutation by combining PNA hybridization and MALDI-TOF mass analysis.Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay.Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.Emerging therapies of hepatitis B and C.Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitroLamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and SafetyResponse to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B.Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus.Targets of emerging therapies for viral hepatitis B and C.Viral dynamics in hepatitis B virus infection.Molecular mechanisms underlying HBsAg negativity in occult HBV infection.Mutations outside the YMDD motif in the P protein can also cause DHBV resistant to Lamivudine.Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler.In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.Modulation of the metabolism of beta-L-(-)-2',3'-dideoxy-3'-thiacytidine by thymidine, fludarabine, and nitrobenzylthioinosine.Pyrosequencing for detection of lamivudine-resistant hepatitis B virus.Computational model of hepatitis B virus DNA polymerase: molecular dynamics and docking to understand resistant mutations.Review: Present and future directions in the treatment of chronic hepatitis B infection.In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC.Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase.The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.Dynamics of hepatitis B virus resistance to lamivudine.Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture.Inhibitory effect of a nucleotide analog on infectious salmon anemia virus infection.
P2860
Q24675792-F1301FF1-F918-4EA1-B87E-04F78B17B82CQ24682078-AA3393BF-E10B-41DE-A981-A94F34E404C9Q28365198-53E95D1B-2541-4A68-9F27-BBEE9008E431Q28379623-593D8BC7-F0B0-4153-AFE2-FED7DA563EF0Q31064047-CDD70E06-FF41-4ABC-A113-27F53FCC9698Q33801322-93D9A90B-E03B-413B-BBB9-74A859F024B6Q33961795-CA631508-8268-400D-87A3-460FB1677F13Q33972465-EBC4B064-F00B-40FA-80E0-0A1981517B6FQ33978482-0384B0C0-C347-4E8E-B26D-8B0DF750AD7AQ34027579-CD48A0FF-F031-4978-BB43-BCF2D2714B6CQ34045308-E5D4ABAB-091D-478A-B3CA-C01704DE7C7AQ34068574-8A622EC5-58A9-45F0-AA31-D75D3B5E4F48Q34330228-98A02850-5B51-49ED-906D-2BF1B0DA0496Q34638684-084C95AD-302D-4CFC-BC2A-F3BDF936D10BQ34720217-78D4034D-8898-474A-A5F4-1C1C48776332Q35014297-3484EF7C-7427-40FA-B403-7EF43147A0F1Q35048263-F17627DA-1851-4355-BDEF-B4FBAB8BB7C4Q35126374-4E4BA122-AB8A-4738-957C-7D9BC864E986Q35359761-0279DEE7-5F12-4B3D-AC09-1E659098D387Q35535861-EF53EF24-29AB-440B-9515-DF575164824AQ36177722-4D084081-C604-4835-8D31-C000B3FCAB8CQ36304057-3647BA8D-8BC2-4135-A0C4-09EFF03787B7Q36548897-D2329A57-7BD7-4B5D-8AAC-C26801C69970Q36653655-BAC7500B-0395-4475-803F-3FE1FED49B03Q37638400-B385A6D0-BC8C-45DB-AF16-A4A819A56D52Q38536404-B8E1013E-3F67-4475-A1E2-6B86E684EF12Q39061363-4C0BE1A2-BD52-4D79-A13B-507532A0F979Q39455322-0D2ADA7F-2CD3-4866-B95A-1B409268FB61Q39464149-D6945779-9ABE-4674-A0DB-58F3DDC44891Q39559675-EB436FED-8159-4ED2-9269-DD01C64E7C9FQ39784049-926DC828-53D1-4679-9B66-562E126A2E7AQ40179921-0A816391-48BD-4B88-B12C-32B26D31D9CDQ40454877-FD49C790-AC37-4391-B5CF-D7CA42FC804AQ40866538-C6FCE6AF-539C-4D58-B8A4-106036B10F3AQ40983950-E5B72344-53E8-40EB-8F67-E0438B7C5AB8Q41503130-09DC3D7B-029E-4E25-A399-21BCB21F684FQ41612943-5C7B8C0F-3941-4001-A1CC-299925A80DABQ41908360-96755E2F-B7BC-4155-9E1F-52847CFE10B8Q42041585-35CDD661-700B-49EB-901D-89BA4F7D3908Q42113871-8A8B8BE4-E052-4D1B-B813-141BCA118997
P2860
Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Mechanism of inhibition of duc ...... -2',3'-dideoxy-3'-thiacytidine
@ast
Mechanism of inhibition of duc ...... -2',3'-dideoxy-3'-thiacytidine
@en
Mechanism of inhibition of duc ...... -2',3'-dideoxy-3'-thiacytidine
@nl
type
label
Mechanism of inhibition of duc ...... -2',3'-dideoxy-3'-thiacytidine
@ast
Mechanism of inhibition of duc ...... -2',3'-dideoxy-3'-thiacytidine
@en
Mechanism of inhibition of duc ...... -2',3'-dideoxy-3'-thiacytidine
@nl
prefLabel
Mechanism of inhibition of duc ...... -2',3'-dideoxy-3'-thiacytidine
@ast
Mechanism of inhibition of duc ...... -2',3'-dideoxy-3'-thiacytidine
@en
Mechanism of inhibition of duc ...... -2',3'-dideoxy-3'-thiacytidine
@nl
P2093
P2860
P356
P1476
Mechanism of inhibition of duc ...... -2',3'-dideoxy-3'-thiacytidine
@en
P2093
P2860
P304
P356
10.1128/AAC.39.7.1430
P407
P577
1995-07-01T00:00:00Z